Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive form of the disease traditionally treated with surgical removal of the bladder. The study, published in the Proceedings of the National Academy of Sciences, demonstrates that ultra-sensitive testing of tumor-derived DNA in blood and urine may help identify patients who can safely preserve their bladder without compromising cancer outcomes.
This article was originally published on MedicalXpress.com
